Scilex Holding has finalized its $150 million strategic investment in Datavault AI through an unconventional payment structure that saw the second tranche settled in Bitcoin. This move signals a dramatic strategic pivot for the biotechnology firm as it ventures beyond its traditional focus areas.
Strategic Shift Toward Data Monetization
The completed transaction involved the full exercise of a pre-funded warrant, resulting in Scilex acquiring approximately 263.91 million shares of Datavault AI common stock. This follows an initial $8 million payment made in September that also utilized Bitcoin. The cryptocurrency-based approach to such a substantial corporate investment highlights increasing institutional acceptance of digital assets for major financial transactions.
Wall Street’s Cautious Stance Meets Transformation Potential
Market professionals are closely monitoring this development. Three Wall Street analysts currently maintain a “Reduce” rating on Scilex shares, with an average price target of $630. In early trading, the stock retreated as much as 3.65%, though investor attention appears focused on long-term strategic implications rather than short-term price movements.
Should investors sell immediately? Or is it worth buying Scilex?
The partnership aims to leverage Datavault AI’s technology for monetizing real-world assets and data, potentially opening significant new revenue streams beyond Scilex’s established pain management portfolio. This foray into artificial intelligence and data monetization could fundamentally reshape the company’s valuation framework and market positioning.
Balancing Core Business with Future Growth
While pursuing this transformative acquisition, Scilex continues to advance its core pharmaceutical products. The company maintains its target of achieving complete debt elimination by the end of 2025. The successful integration of Datavault AI’s technologies is expected to become a crucial performance driver by 2026, potentially altering Scilex’s competitive standing within the biotechnology sector.
The convergence of biotechnology and artificial intelligence through this Bitcoin-facilitated deal represents a notable evolution in corporate financing strategies and cross-industry collaboration.
Ad
Scilex Stock: Buy or Sell?! New Scilex Analysis from January 12 delivers the answer:
The latest Scilex figures speak for themselves: Urgent action needed for Scilex investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 12.
Scilex: Buy or sell? Read more here...
